BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced a collaboration with one of the world’s premier research centers for rheumatoid arthritis (RA), the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM).

波士顿--（商业新闻短讯）--DeepCure是一家利用人工智能发现炎症和免疫疾病新药的治疗公司，今天宣布与世界首屈一指的类风湿性关节炎（RA）研究中心之一的利兹风湿与肌肉骨骼医学研究所（LIRMM）合作。

The collaboration will investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for over a million patients worldwide with RA who do not respond well to current standard of care..

该合作将研究DC-9476，一种第三代选择性BRD4（BD2）抑制剂，作为全球100多万对当前护理标准反应不佳的RA患者的潜在治疗方法。。

DC-9476 is a development candidate that inhibits the Brd4 protein which belongs to the BET family of proteins. DC-9476 decreases tissue and blood levels of cytokines that are key regulators of innate and adaptive immunity, such as TNF-alpha, IL6, IL-17, and IL-1b, which are up-regulated in autoimmune diseases.

。DC-9476降低作为先天性和适应性免疫的关键调节剂的细胞因子的组织和血液水平，例如在自身免疫性疾病中上调的TNF-α，IL6，IL-17和IL-1b。

The development candidate is designed to have greater selectivity for Brd4 and BD2 than previous generations of BET inhibitors to increase safety. In preclinical RA models, DC-9476 demonstrated better safety and efficacy compared to RA treatments that are the standard of care, including TNF-inhibitors and JAK inhibitors..

。在临床前RA模型中，与作为标准治疗的RA治疗（包括TNF抑制剂和JAK抑制剂）相比，DC-9476表现出更好的安全性和有效性。。

The experienced team at LIRMM will investigate DC-9476 using blood samples and joint biopsies from multiple patient subgroups, in combination with the advanced translational tools developed at the institute. In particular, the studies will focus on samples from patients that are classified as difficult to treat or refractory to current approved therapies.

LIRMM经验丰富的团队将使用来自多个患者亚组的血液样本和关节活检，结合研究所开发的先进翻译工具，对DC-9476进行调查。特别是，这些研究将重点关注那些被归类为难以治疗或对目前批准的治疗无效的患者的样本。

The studies will include examining gene expression patterns and cytokines measurements in patient cells and tissues..

这些研究将包括检查患者细胞和组织中的基因表达模式和细胞因子测量。。

“We are thrilled to collaborate with DeepCure on this innovative project,” said Dr. Kulveer Mankia, Clinical Associate Professor and Honorary Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital. “DC-9476 may represent a novel approach to treating people with RA who have not responded well to current therapies and have limited treatment options.

Chapel Allerton医院利兹风湿病和肌肉骨骼医学研究所临床副教授兼荣誉顾问风湿病学家Kulveer Mankia博士说：“我们很高兴与DeepCure合作进行这一创新项目。”。“DC-9476可能代表了一种治疗RA患者的新方法，这些患者对目前的治疗反应不佳，治疗选择有限。

We believe these patients could potentially benefit from DC-9476 due to its activity against multiple immune pathways, and we are hopeful that this partnership will lead to a significant breakthrough for patients.”.

我们相信这些患者可能会受益于DC-9476，因为它具有抗多种免疫途径的活性，我们希望这种伙伴关系将为患者带来重大突破。”。

“We’re excited to work with the clinicians and scientists at LIRMM and will benefit from their deep expertise in the complexities of RA and the unmet needs of patients,” said Kfir Schreiber, CEO & Co-Founder of DeepCure. “This collaboration allows us to evaluate the efficacy of DC-9476 in patient-derived samples and help identify RA patient subgroups that will benefit the most from this compound.”.

DeepCure首席执行官兼联合创始人Kfir Schreiber表示：“我们很高兴与LIRMM的临床医生和科学家合作，并将受益于他们在RA复杂性和患者未满足需求方面的深厚专业知识。”。“这种合作使我们能够评估DC-9476在患者来源样本中的疗效，并帮助确定将从该化合物中获益最多的RA患者亚组。”。

About DeepCure

关于DeepCure

DeepCure was founded by researchers at MIT to accelerate breakthrough therapies using artificial intelligence (AI) and AI-enabling technologies to innovate small molecule discovery. The company is based in Boston, MA, and its engineers, chemists, and biologists collaborate on hard problems to find solutions that will have an enormous impact on patient health.

DeepCure由麻省理工学院的研究人员创立，旨在利用人工智能（AI）和人工智能技术创新小分子发现，加速突破性治疗。该公司总部位于马萨诸塞州波士顿，其工程师、化学家和生物学家合作解决棘手的问题，以找到对患者健康产生巨大影响的解决方案。

For more information, visit www.deepcure.ai..

有关更多信息，请访问www.deepcure.ai。。